OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research report released on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of NASDAQ:OPGN opened at $1.90 on Thursday. The stock’s 50-day moving average is $1.93 and its 200 day moving average is $3.06. OpGen has a 1 year low of $1.61 and a 1 year high of $9.90.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The company had revenue of $0.03 million during the quarter.

Hedge Funds Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent filing with the Securities and Exchange Commission. 2.68% of the stock is owned by institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.